Bristol Myers uncorks positive PhIII readout for subcutaneous Opdivo
Bristol Myers Squibb’s subcutaneous formulation of its cancer blockbuster Opdivo proved noninferior to intravenous Opdivo in a Phase III trial, the company
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.